Fuzzy thinking on biomarkers

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 2, 2007, Pages 97-100

  Stadler, Walter ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

CANCER RISK; DEVELOPMENT; EDITORIAL; PRIORITY JOURNAL; PROSTATE CANCER; UROGENITAL TRACT CANCER;

DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847341555     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.10.005     Document Type: Editorial

References (28)

1. Dignam J., Bryant J., and Paik S. Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy. Methods Mol Biol 184 (2002) 169-189
2. Hayes D.F., Bast R.C., Desch C.E., et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88 (1996) 1456-1466
3. Pajak T.F., Clark G.M., Sargent D.J., et al. Statistical issues in tumor marker studies. Arch Pathol Lab Med 124 (2000) 1011-1015
4. Simon R., and Altman D.G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69 (1994) 979-985
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
6. Epstein J.I., and Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J Urol 175 (2006) 820-834
7. Joniau S., Goeman L., Pennings J., et al. Prostatic intraepithelial neoplasia (PIN): Importance and clinical management. Eur Urol 48 (2005) 379-385
8. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
9. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
10. Bostwick D.G. Grading prostate cancer. Am J Clin Pathol 102 (1994) S38-S56
11. Carlson G.D., Calvanese C.B., Kahane H., et al. Accuracy of biopsy Gleason scores from a large uropathology laboratory: Use of a diagnostic protocol to minimize observer variability. Urology 51 (1998) 525-529
12. Sengupta S., Slezak J.M., Blute M.L., et al. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer 106 (2006) 2630-2635
13. Gonzalgo M.L., Bastian P.J., Mangold L.A., et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 67 (2006) 115-119
14. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev (2001) CD000486
15. Iversen P., Rasmussen F., and Christensen I.J. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 157 (1994) 41-47
16. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
17. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98 (2006) 516-521
18. Prentice R.L. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8 (1989) 431-440
19. Collette L., Burzykowski T., Carroll K.J., et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?. Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 23 (2005) 6139-6148
20. Roehrborn C.G., Pickens G.J., and Carmody III T. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology 47 (1996) 59-66
21. Glenski W.J., Klee G.G., Bergstralh E.J., et al. Prostate-specific antigen: Establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. Prostate 21 (1992) 99-110
22. Herrmann M., Scharhag J., Sand-Hill M., et al. Long-distance mountain biking does not disturb the measurement of total, free or complexed prostate-specific antigen in healthy men. Clin Chem Lab Med 42 (2004) 347-349
23. Brawer M.K., Bankson D.D., Haver V.M., et al. Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method. Prostate 30 (1997) 269-273
24. Jung K., Lein M., Brux B., et al. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions. Clin Chem Lab Med 38 (2000) 1271-1275
25. Simon R., Radmacher M.D., and Dobbin K. Design of studies using DNA microarrays. Genet Epidemiol 23 (2002) 21-36
26. Sargent D.J., Conley B.A., Allegra C., et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23 (2005) 2020-2027
27. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
28. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512